The hepatic clearance of recombinant tissue-type plasminogen activator decreases after an inflammatory stimulus

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 1, 2000, Pages 119-125

  Nagaoka, M R ^a   Kouyoumdjian, M ^a   Borges, D R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Inflammation; Kallikrein; Liver clearance; Thrombin; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE; PLASMA KALLIKREIN; THROMBIN; TISSUE KALLIKREIN; TURPENTINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; INFLAMMATION; LIVER CLEARANCE; MALE; NONHUMAN; RAT; TISSUE DISTRIBUTION;

EID: 0033964339     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000100016     Document Type: Article

References (26)

1. Roberts HR, Monroe DM, Oliver JA, Chang J-Y & Hoffman M (1998). Newer concepts of blood coagulation. Haemophilia, 4: 331-334.
2. Levi M & Ten Cate H (1999). Disseminated intravascular coagulation. New England Journal of Medicine, 341: 586-592.
3. Otter M, Kuiper J, Bos R, Rijken DC & van Berkel ThJC (1992). Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA. Biochemical Journal, 284: 545-550.
4. Narita M, Bu G, Herz J & Schwartz AL (1995). Two receptor systems are involved in the plasma clearance of tissue-type plasm nogen activator (t-PA) in vivo. Journal of Clinical Investigation, 96: 1164-1168.
5. Borges DR & Gordon AH (1976). Kininogen and kininogenase synthesis by the liver of normal and injured rats. Journal of Pharmacy and Pharmacology, 28: 44-48.
6. Barlas A, Okamoto H & Greenbaum LM (1985). T-kininogen - the major plasma kininogen in rat adjuvant arthritis. Biochemical and Biophysical Research Communications, 129: 280-286.
7. Limãos EA, Borges DR, Souza-Pinto JC, Gordon AH & Prado JL (1981). Acute turpentine inflammation and kinin release in rat-paw thermic oedema. British Journal of Experimental Pathology, 62: 591-594
8. Colman RW & Schmaier AH (1997). Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood, 90: 3819-3843.
9. Brown NJ, Nadeau JH & Vaughan DE (1997). Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thrombosis and Haemostasis, 77: 522-525.
10. Leiper K, Croll A, Booth NA, Moore NR, Sinclair T & Bennett B (1994). Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. Journal of Clinical Pathology, 47: 214-217.
11. Martins B, Kouyoumdjian M, Limãos EA & Borges DR (1992). The clearance rate of plasma kallikrein by the liver increases during acute-phase response to inflammation. Agents and Actions, 37: 111-113.
12. Wong MWC & Jamieson JC (1979). Evidence for reduced uptake of asialo-alpha 1-acid glycoprotein during the acute-phase response to inflammation. Life Sciences, 25: 827-834.
13. Nagaoka MR, Kouyoumdjian M & Borges DR (1996). Plasma kallikrein and tissue-type plasminogen activator compete for a common pathway into the liver. Immunopharmacology, 32: 88-90.
14. Kouyoumdjian M, Borges DR, Prado ES & Prado JL (1989). Identification of receptors in the liver that mediate endocytosis of circulating tissue kallikreins. Biochimica et Biophysica Acta, 980: 299-304.
15. Weyer B, Petersen TE & Sonne O (1988). Characterization of the binding of bovine thrombin to isolated rat hepatocytes Thrombosis and Haemostasis, 60: 419-427.
16. International Guiding Principles for Biomedical Research Involving Animals by the Council for International Organizations of Medical Sciences (CIOMS) (1985). Geneva, Switzerland, 1-28.
17. Sarphie TG, D'Souza NB & Deaciuc IV (1996) Kupffer cell inactivation prevents lipopolysaccharide-induced structural changes in the rat liver sinusoid: an electron-microscopic study. Hepatology, 23: 788-796.
18. Borges DR & Kouyoumdjian M (1992). Chloramine T impairs the receptor-mediated endocytosis of plasma kallikrein by the liver. Agents and Actions, 38 (Suppl II): 278-284.
19. Lottenberg R, Christensen U, Jackson CM & Coleman PL (1981). Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods in Enzymology, 80: 341-361.
20. Borges DR, Gordon AH, Guimarães JA & Prado JL (1985). Rat plasma kallikrein clearance by perfused rat liver. Brazilian Journal of Medical and Biological Research, 18: 187-194.
21. Nagaoka MR, Kouyoumdjian M & Borges DR (1997). Cava vein perfusion in situ: a tool for uptake studies. Journal of Pharmacological and Toxicological Methods, 37: 23-26.
22. Borges DR & Kouyoumdjian M (1994). Plasma kallikrein clearance by the liver: a review. Brazilian Journal of Medical and Biological Research, 27: 2033-2041.
23. Ieko M, Sawada K, Yasukouchi T, Sakurama S, Tohma Y, Shiroshita K, Kurosawa S, Ohmoto A, Kohno M, Satoh M & Koike T (1997). Protection by α2-macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor-1. British Journal of Haematology, 97: 214-218.
24. Ebner R & Derynck R (1991). Epidermal growth factor and transforming growth factor-α: Differential intracellular routing and processing of ligand-receptor complexes. Cell Regulation, 2: 599-612.
25. Olaso E & Friedman SL (1998). Molecular regulation of hepatic fibrogenesis. Journal of Hepatology, 29: 836-847.
26. The National Institute of Neurological Disorders and Stroke. r-t-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine, 333: 1581-1587.